Interval Cancer Characteristics, Staging and Survival Among National Bowel Cancer Screening Program Participants, Western Australia, 2018: A Retrospective Observational Cohort Study.
코호트
1/5 보강
[OBJECTIVE] To examine the features of interval colorectal cancer (interval CRC) in Western Australia in the context of the National Bowel Cancer Screening Program (NBCSP), including incidence, charac
- 95% CI 3-11
- 추적기간 33 months
- 연구 설계 cohort study
APA
Smith SJ, Moorin R, et al. (2026). Interval Cancer Characteristics, Staging and Survival Among National Bowel Cancer Screening Program Participants, Western Australia, 2018: A Retrospective Observational Cohort Study.. The Medical journal of Australia, 224(2), e70138. https://doi.org/10.5694/mja2.70138
MLA
Smith SJ, et al.. "Interval Cancer Characteristics, Staging and Survival Among National Bowel Cancer Screening Program Participants, Western Australia, 2018: A Retrospective Observational Cohort Study.." The Medical journal of Australia, vol. 224, no. 2, 2026, pp. e70138.
PMID
41629194 ↗
Abstract 한글 요약
[OBJECTIVE] To examine the features of interval colorectal cancer (interval CRC) in Western Australia in the context of the National Bowel Cancer Screening Program (NBCSP), including incidence, characteristics and survival by NBCSP participant characteristics.
[STUDY DESIGN] Retrospective observational cohort study, analysis of linked National Cancer Screening Register and Western Australian Cancer Registry data.
[PARTICIPANTS, SETTING] Participants in the Western Australian NBCSP (50-74 years of age) with negative immunochemical faecal occult blood test (iFOBT) results during the 2018 screening round (1 January 2018-31 December 2018) were followed up for interval CRC diagnoses until 31 December 2020, and for death until 30 September 2022.
[MAIN OUTCOME MEASURES] Crude and adjusted incidence rates of interval CRC were analysed overall and by sex, age group and residential socio-economic and remoteness categories. Survival outcomes for people with interval CRC were also assessed.
[RESULTS] Of 122,851 NBCSP participants with negative screening results in 2018, 51 people were diagnosed with interval CRC during follow-up (crude incidence rate, 21 per 100,000 person-years; 95% confidence interval [CI], 16-27). The adjusted incidence rate ratio of interval CRC was higher for men than women (adjusted incidence rate ratio [aIRR], 5; 95% CI, 3-11) and for people aged 70-74 years than for those aged 50-59 years (aIRR, 3; 95% CI, 1-6). Nineteen of 51 interval CRCs were diagnosed 19-24 months after negative iFOBT results, 25 were located on the right side of the colon and 34 were adenocarcinomas. Only 13 interval CRCs were stage I tumours at diagnosis. During follow-up (median, 33 months; interquartile range, 28-42 months), the all-cause mortality rate among the 51 people with interval CRC was 41 per 1000 person-years (95% CI, 18-92), and the colorectal cancer mortality rate was 35 per 1000 person-years (95% CI, 14-83).
[CONCLUSIONS] We provide a comprehensive analysis of interval CRC staging and clinical characteristics in the context of the NBCSP in Western Australia, facilitating the definition of benchmarks for monitoring programme performance.
[STUDY DESIGN] Retrospective observational cohort study, analysis of linked National Cancer Screening Register and Western Australian Cancer Registry data.
[PARTICIPANTS, SETTING] Participants in the Western Australian NBCSP (50-74 years of age) with negative immunochemical faecal occult blood test (iFOBT) results during the 2018 screening round (1 January 2018-31 December 2018) were followed up for interval CRC diagnoses until 31 December 2020, and for death until 30 September 2022.
[MAIN OUTCOME MEASURES] Crude and adjusted incidence rates of interval CRC were analysed overall and by sex, age group and residential socio-economic and remoteness categories. Survival outcomes for people with interval CRC were also assessed.
[RESULTS] Of 122,851 NBCSP participants with negative screening results in 2018, 51 people were diagnosed with interval CRC during follow-up (crude incidence rate, 21 per 100,000 person-years; 95% confidence interval [CI], 16-27). The adjusted incidence rate ratio of interval CRC was higher for men than women (adjusted incidence rate ratio [aIRR], 5; 95% CI, 3-11) and for people aged 70-74 years than for those aged 50-59 years (aIRR, 3; 95% CI, 1-6). Nineteen of 51 interval CRCs were diagnosed 19-24 months after negative iFOBT results, 25 were located on the right side of the colon and 34 were adenocarcinomas. Only 13 interval CRCs were stage I tumours at diagnosis. During follow-up (median, 33 months; interquartile range, 28-42 months), the all-cause mortality rate among the 51 people with interval CRC was 41 per 1000 person-years (95% CI, 18-92), and the colorectal cancer mortality rate was 35 per 1000 person-years (95% CI, 14-83).
[CONCLUSIONS] We provide a comprehensive analysis of interval CRC staging and clinical characteristics in the context of the NBCSP in Western Australia, facilitating the definition of benchmarks for monitoring programme performance.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.